Pluristem Therapeutics (PSTI +4.2%) enjoys continued upward momentum after Thursday's news that it received permission from India's health ministry to proceed with a Phase II clinical trial for the treatment of Buerger's disease. The trial could be followed by a larger multi-national Phase III. Shares popped 10% yesterday on the announcement.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Mar 18, 2013)
at MarketWatch.com (Sep 13, 2012)
at MarketWatch.com (Sep 12, 2012)
at MarketWatch.com (Sep 5, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs